You are here
FasCure Therapeutics LLC
UEI: LNESEBSKBHK8
# of Employees: 1
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Exploiting activation-induced cell death as a means of inducing tolerance to kidney allografts
Amount: $224,999.00PROJECT SUMMARY Kidney transplantation is the preferred treatment for patients with end stage renal diseaseHoweverstandard immunosuppression to control rejection is the major limitationAlthough standa ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
SA FasL engineered human islets as a novel product for the treatment of type diabetes
Amount: $224,529.00PROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affec ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
Amount: $225,000.00DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adj ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
Amount: $224,999.00DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase ...
STTRPhase I2015Department of Health and Human Services National Institutes of Health
